Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
The return on assets (ROA) is -20.36%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -5.49%.
RETURN ON ASSETS (ROA)
-20.36%
RETURN ON ASSETS (ROA) AVG TTM
N/A
RETURN ON ASSETS (ROA) AVG 3Y
N/A
RETURN ON ASSETS (ROA) AVG 5Y
N/A
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.27%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
+36.90%
vs the sector median at left
Starling Oncology, Inc.
Market Cap
$657.89M
Return on Assets (ROA)
-20.36%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$656.59M
Return on Assets (ROA)
-36.37%
TTM Avg
-26.71%
3Y Avg
-31.04%
5Y Avg
-27.33%
Market Cap
$660.29M
Return on Assets (ROA)
-82.36%
TTM Avg
-56.97%
3Y Avg
-52.21%
5Y Avg
-45.34%
Market Cap
$666.95M
Return on Assets (ROA)
-70.67%
TTM Avg
-51.05%
3Y Avg
-54.02%
5Y Avg
-55.25%
Market Cap
$673.41M
Return on Assets (ROA)
2.22%
TTM Avg
15.13%
3Y Avg
10.21%
5Y Avg
1.65%
Market Cap
$638.20M
Return on Assets (ROA)
-37.63%
TTM Avg
-55.16%
3Y Avg
-41.63%
5Y Avg
-48.17%
Market Cap
$681.02M
Return on Assets (ROA)
-98.15%
TTM Avg
-106.83%
3Y Avg
-87.42%
5Y Avg
-76.51%
Market Cap
$681.27M
Return on Assets (ROA)
-49.24%
TTM Avg
-70.53%
3Y Avg
-58.08%
5Y Avg
-52.49%
Market Cap
$634.30M
Return on Assets (ROA)
19.25%
TTM Avg
-15.00%
3Y Avg
-19.98%
5Y Avg
-33.37%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Starling Oncology, Inc. (STLN) | $657.89M | -20.36% | N/A | N/A | N/A |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $656.59M | -36.37% | -26.71% | -31.04% | -27.33% |
| Annexon, Inc. (ANNX)vs › | $660.29M | -82.36% | -56.97% | -52.21% | -45.34% |
| Helus Pharma Inc. (HELP)vs › | $666.95M | -70.67% | -51.05% | -54.02% | -55.25% |
| MiMedx Group, Inc. (MDXG)vs › | $673.41M | 2.22% | 15.13% | 10.21% | 1.65% |
| Aura Biosciences, Inc. (AURA)vs › | $638.20M | -37.63% | -55.16% | -41.63% | -48.17% |
| Verastem, Inc. (VSTM)vs › | $681.02M | -98.15% | -106.83% | -87.42% | -76.51% |
| Solid Biosciences Inc. (SLDB)vs › | $681.27M | -49.24% | -70.53% | -58.08% | -52.49% |
| Zevra Therapeutics, Inc. (ZVRA)vs › | $634.30M | 19.25% | -15.00% | -19.98% | -33.37% |
| Prime Medicine, Inc. (PRME)vs › | $632.16M | -75.45% | -62.27% | -65.14% | -53.59% |
ROA
-20.4%
ROE
N/A
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -36.81% |
